Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.86 EUR | -2.05% | -3.37% | +25.36% |
May. 23 | Prysmian among best; euro advances on dollar | AN |
May. 15 | Farmacosmo, group revenues drop into single digits in first quarter | AN |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.48 for the 2024 fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Department Stores
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+25.36% | 36.2M | - | ||
+2.47% | 45.23B | B | ||
+40.46% | 40.66B | - | ||
+13.35% | 10.11B | B | ||
-21.69% | 7.42B | C | ||
-3.58% | 7.25B | C | ||
+15.84% | 6.95B | B- | ||
-5.61% | 5.62B | D+ | ||
+7.70% | 5.24B | C | ||
-50.74% | 3.9B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- COSMO Stock
- Ratings Farmacosmo S.p.A.